Nomic
Nomic Bio is a Montreal-based proteomics company that uses proprietary DNA-nanotechnology-enabled nELISA assays to deliver industrial-scale, high-plex protein profiling at $50 per sample, serving pharmaceutical, biotechnology, and academic research customers worldwide with end-to-end profiling services and analysis software.
- Company typePrivate
- Founded2021
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nomic does
Nomic Bio Inc. is a Montreal-based proteomics company founded in 2021 by Milad Dagher and David Juncker, with US operations in Somerville, Massachusetts. The company has built its business around a proprietary technology called nELISA, a sandwich immunoassay platform that uses DNA nanotechnology to pre-colocalize antibody pairs on spectrally encoded microparticles, enabling massively multiplexed protein quantification while eliminating cross-reactivity. Read-out is performed via flow cytometry at industrial scale, achieving ~0.1 pg/mL sensitivity, 99.99% specificity, 3-6 log dynamic range, and <10% intra-lot CV.
Nomic commercializes this technology through a modular portfolio of products and services. Its flagship product is Omni 1000, which delivers absolute quantification of 1,000+ proteins in a single assay at approximately $50 per sample, designed to make proteome-wide studies economically feasible for well-powered research. Supporting products include context-specific Core panels (~300 proteins each, such as Core Immune and Core CardioMet) and Flex, an a la carte selection from the full 1,050+ protein library. Customers access results through the Nomic Portal, a SaaS data-analysis platform. The company also runs an end-to-end mail-in protein profiling service with turnaround times as fast as one week, processing tens of thousands of samples weekly.
Nomic's go-to-market is primarily direct sales, supported by expert application scientists, and serves pharmaceutical companies (including top-10 pharma), innovative biotechs, academic research institutes, and CROs. Pricing is usage-based at the sample level. The company has raised over $60 million across a $17 million Series A (led by Lux Capital in December 2021) and a $42 million oversubscribed Series B (led by a US-based life-sciences investor in September 2024), and operates with 11-50 employees across both offices. Notable partnerships include research collaborations with Parker Institute for Cancer Immunotherapy, Broad Clinical Labs, Wellcome Sanger Institute, and the HESI Global OASIS Consortium, alongside a foundational Nature Methods publication of the nELISA technology in November 2025.
Nomic firmographics
Firmographics- Name
- Nomic
- Legal name
- Nomic Bio Inc.
- Website
- https://nomic.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nomic Bio is a Montreal-based proteomics company that uses proprietary DNA-nanotechnology-enabled nELISA assays to deliver industrial-scale, high-plex protein profiling at $50 per sample, serving pharmaceutical, biotechnology, and academic research customers worldwide with end-to-end profiling services and analysis software.
- Ownership category
- akta.pro rank
Nomic industry classification
Industry- Product category
- Proteomics Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Nomic is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Nomic business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Protein Profiling Service: End-to-end protein profiling service where customers ship samples and receive quantitative protein data. Pricing is based on per-sample analysis with turnaround times as fast as one week. The service is designed for high-throughput industrial-scale proteomics.
- Platform Licensing/Access: Customers access the nELISA platform technology through service agreements, with options for different panel configurations (Omni 1000, Core, Flex) depending on their research needs.
- Collaborations and Grants: The company offers grant programs like the Omni 1000 Grant Opportunity enabling institutional access to proteomics technology for research purposes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Omni 1000 - 1,000+ proteins with absolute quantification |
| Usage-based | Pay-as-you-go | Core Panels - ~300 protein context-specific panels |
| Usage-based | Pay-as-you-go | Flex - Custom panel selection from full library |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Nomic product offering
Product offeringCore offering
Nomic develops and operates a proprietary nELISA proteomics platform that combines DNA nanotechnology with bead-based immunoassays and flow cytometry to quantify proteins at high multiplexing and high throughput. The company sells protein profiling services and panel products (Omni 1000, Core Immune, Core CardioMet, Flex) to pharmaceutical, biotechnology, and academic customers, who ship samples to Nomic and receive analysis-ready data through the Nomic Portal. Pricing for the flagship Omni 1000 panel starts at approximately $50 per sample for absolute quantification of 1,000+ proteins, with turnaround times as fast as one week.
Product overview
Nomic offers a modular proteomics platform centered on its proprietary nELISA technology, providing scalable, quantitative protein profiling. The portfolio includes Omni 1000 (1,000+ protein panel at ~$50/sample), Core Immune and Core CardioMet panels (~300 proteins each), and Flex (custom a la carte selection). Data analysis is delivered through the Nomic Portal, while the company also provides end-to-end profiling services with expert support and turnaround times as fast as one week.
Differentiator
Problem solved
Functional benefit
Brands
- nELISA: Proprietary high-throughput, massively multiplexed immunoassay platform for protein profiling using DNA nanotechnology with bead-based readout
- Omni 1000
- Core
- Flex
- Nomic Portal
Products and services
- Omni 1000 High-throughput, proteome-wide panel that measures 1,000+ rigorously selected proteins with absolute quantification (pg/mL) at approximately $50 per sample. Designed for large-scale perturbation screens, population-scale cohorts, and AI-ready proteomic datasets. For pharmaceutical, biotech, and academic research customers.
- Core Immune Context-specific ~300-protein panel delivering comprehensive coverage of the immune landscape, capturing 95.4% of major immune pathways and key inflammatory markers. Curated from scientific literature, widely used mid-plex panels, and established endpoint tests. For immunology and inflammation research teams.
- Core CardioMet Context-specific ~300-protein panel covering cardiac and metabolic biology, capturing 14 out of 15 cardiometabolic KEGG disease pathways. Content anchored in high-value MVP proteins from literature, mid-plex panels, and UK Biobank proteomics datasets. For cardiometabolic research teams.
- Flex À la carte protein selection service that lets researchers build custom panels from Nomic's full protein library of 1,050+ proteins, aligned with specific study goals without the usual restrictions of predefined panels.
- Nomic Portal Cloud-based SaaS data analysis and visualization platform providing intuitive tools for exploring proteomic datasets. Features include UMAP visualization, volcano plots, clustergrams, dose-response curves, most-variable-protein identification, and fold-change transformations with automated pipelines.
- Protein Profiling Service End-to-end industrial-grade mail-in protein profiling service that supports sample submission, expert application scientist support, automated processing, and turnkey data delivery through the Nomic Portal. Turnaround times as fast as one week, with capacity for tens of thousands of samples per week. For pharma, biotech, academic, and CRO customers.
Quantifiable outcome
- 950,000+ samples profiled across 150+ institutions
- +5 more outcomes
Companies that use Nomic
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
Nomic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature7 records
Nomic partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- HESI Global OASIS ConsortiumcorePartnership to identify biomarker signatures for liver toxicity using large-scale protein profiling of 3,000+ HepaRG cell samples treated with 168 compounds for predictive toxicity models.
- Wellcome Sanger InstituteflagshipResearch collaboration through Project JAGUAR to perform large-scale proteomic profiling of 1,500+ PBMC samples, integrating proteomic data with genetic and transcriptomic information to build a functional atlas of human immune variation.
- Broad Clinical Labs (BCL)flagshipIntegration of Nomic's Omni 1000 platform into BCL's multi-omic workflows for discovery and translational research. Jointly branded solutions planned for early 2027 with applications in risk assessment, precision oncology, and biomarker development.
- Parker Institute for Cancer Immunotherapy (PICI)flagshipResearch collaboration to quantify circulating protein biomarkers in ~3,000 patient blood samples from PICI's RADIOHEAD study using nELISA platform. Aims to understand how patients respond to immunotherapy across cancer types.
- JUMP Cell Painting ConsortiumcoreNomic provides nELISA to profile 200 secreted proteins for 10,000 samples, generating 2 million protein data points to complement cell morphology data for phenotypic drug discovery.
Scale indicators11 records
Recent moves6 records
Expansion highlights7 records
Nomic competitors and assessment
Company assessmentBroad incumbents
- Abcam: Established research-reagent supplier of antibodies and immunoassay kits; competes broadly with Nomic's antibody-driven proteomics and offers adjacent tools for academic and pharma protein research.
- Bio-Techne: Large life-sciences tools company offering antibodies, ELISA kits, Luminex multiplex assays (via ProteinSimple), and proteomics reagents. A broad incumbent that overlaps with Nomic in research-use proteomics consumables and kits.
Direct peers
- Meso Scale Diagnostics (MSD): Multiplexed electrochemiluminescence immunoassay platform (Meso Scale Discovery / V-PLEX) widely adopted in pharma for biomarker and cytokine profiling. Competes with Nomic's Core panels and broader pharma proteomics use cases.
- Quanterix: Developer of ultra-sensitive single-molecule array (Simoa) immunoassays for protein detection at sub-pg/mL levels. Overlaps with Nomic's high-sensitivity proteomics positioning in neurology, oncology, and inflammation research.
- Seer: Proteomics company using engineered nanoparticle technology (Proteograph) for deep, unbiased plasma proteomics. Competes with Nomic in pharma discovery and translational research, with a different technology approach to the same customer base.
- Standard BioTools (SomaLogic): Operates the SomaScan SOMAmer-modified-aptamer proteomics platform measuring 7,000+ proteins, a direct competitor to Nomic's high-plex immunoassay platform. Both target pharma biomarker discovery and translational research with quantitative proteomics.
- Luminex (DiaSorin): Bead-based multiplex immunoassay platform (xMAP / MAGPIX) for cytokine, biomarker, and protein profiling. Direct overlap with Nomic's mid-plex panel offerings and pharma research use cases.
- Olink Holding (now part of Thermo Fisher Scientific): Direct competitor offering proximity-extension-assay (PEA) based multiplexed proteomics panels (Target 96/48, Explore 3072) with absolute quantification and large pharma adoption. Operates in the same high-plex proteomics space Nomic targets with Omni 1000.
Emerging players
- 10x Genomics: Multi-omic tools company with single-cell and spatial platforms that increasingly integrate with proteomics; overlapping customer base in pharma translational research and complements Nomic's PBMC/perturbation work.
- Alamar Biosciences: Early-stage proteomics company developing high-sensitivity, ultra-plex proximity-based assays (NULISA) targeting low-abundance proteins in plasma. Comparable to Nomic in customer profile (biopharma, translational research) and pricing disruption narrative.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Nomic social profiles
Digital presenceNomic compliance and trust
Trust signalCompliance2 records
Nomic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nomic leadership team
Management profileNumber of profiles
Profiles5 records
Nomic funding detail
Funding detailFunding overview
Funding rounds9 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nomic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nomic
What does Nomic do?
Nomic develops and operates a proprietary nELISA proteomics platform that combines DNA nanotechnology with bead-based immunoassays and flow cytometry to quantify proteins at high multiplexing and high throughput. The company sells protein profiling services and panel products (Omni 1000, Core Immune, Core CardioMet, Flex) to pharmaceutical, biotechnology, and academic customers, who ship samples to Nomic and receive analysis-ready data through the Nomic Portal. Pricing for the flagship Omni 1000 panel starts at approximately $50 per sample for absolute quantification of 1,000+ proteins, with turnaround times as fast as one week.
Is Nomic a public or private company?
Nomic is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nomic founded?
Nomic was founded in 2021. It employs 11 to 50 people.
Where is Nomic based?
Nomic is headquartered in Montréal, Canada, in the North America region.
How does Nomic make money?
Three revenue lines are on record. Protein Profiling Service is the primary driver. The others are platform Licensing/Access and collaborations and Grants.
Who are Nomic's main competitors?
Broad incumbents on record are Abcam and Bio-Techne. Direct peers are Meso Scale Diagnostics (MSD), Quanterix, Seer, Standard BioTools (SomaLogic), Luminex (DiaSorin) and Olink Holding (now part of Thermo Fisher Scientific). Emerging players are 10x Genomics and Alamar Biosciences.
Does Nomic have an API?
No public API is recorded for Nomic.
What industry is Nomic in?
Nomic's product category is Proteomics Services. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.